BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jin XF, Spoettl G, Maurer J, Nölting S, Auernhammer CJ. Inhibition of Wnt/β-Catenin Signaling in Neuroendocrine Tumors in vitro: Antitumoral Effects. Cancers (Basel) 2020;12:E345. [PMID: 32033025 DOI: 10.3390/cancers12020345] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
Number Citing Articles
1 Wu H, Yu Z, Liu Y, Guo L, Teng L, Guo L, Liang L, Wang J, Gao J, Li R, Yang L, Nie X, Su D, Liang Z. Genomic characterization reveals distinct mutation landscapes and therapeutic implications in neuroendocrine carcinomas of the gastrointestinal tract. Cancer Commun (Lond) 2022. [PMID: 36264285 DOI: 10.1002/cac2.12372] [Reference Citation Analysis]
2 Pozas J, Alonso-Gordoa T, Román MS, Santoni M, Thirlwell C, Grande E, Molina-Cerrillo J. Novel therapeutic approaches in GEP-NETs based on genetic and epigenetic alterations. Biochim Biophys Acta Rev Cancer 2022;1877:188804. [PMID: 36152904 DOI: 10.1016/j.bbcan.2022.188804] [Reference Citation Analysis]
3 Hescheler DA, Hartmann MJM, Riemann B, Michel M, Bruns CJ, Alakus H, Chiapponi C. Targeted Therapy for Adrenocortical Carcinoma: A Genomic-Based Search for Available and Emerging Options. Cancers (Basel) 2022;14:2721. [PMID: 35681700 DOI: 10.3390/cancers14112721] [Reference Citation Analysis]
4 Danesh Pouya F, Rasmi Y, Nemati M. Signaling Pathways Involved in 5-FU Drug Resistance in Cancer. Cancer Invest 2022;:1-28. [PMID: 35320055 DOI: 10.1080/07357907.2022.2055050] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Maharjan CK, Ear PH, Tran CG, Howe JR, Chandrasekharan C, Quelle DE. Pancreatic Neuroendocrine Tumors: Molecular Mechanisms and Therapeutic Targets. Cancers (Basel) 2021;13:5117. [PMID: 34680266 DOI: 10.3390/cancers13205117] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 11.0] [Reference Citation Analysis]
6 Rinke A, Auernhammer CJ, Bodei L, Kidd M, Krug S, Lawlor R, Marinoni I, Perren A, Scarpa A, Sorbye H, Pavel ME, Weber MM, Modlin I, Gress TM. Treatment of advanced gastroenteropancreatic neuroendocrine neoplasia, are we on the way to personalised medicine? Gut 2021;70:1768-81. [PMID: 33692095 DOI: 10.1136/gutjnl-2020-321300] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 10.0] [Reference Citation Analysis]
7 Yu F, Yu C, Li F, Zuo Y, Wang Y, Yao L, Wu C, Wang C, Ye L. Wnt/β-catenin signaling in cancers and targeted therapies. Signal Transduct Target Ther 2021;6:307. [PMID: 34456337 DOI: 10.1038/s41392-021-00701-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 31] [Article Influence: 25.0] [Reference Citation Analysis]
8 Nölting S, Bechmann N, Taieb D, Beuschlein F, Fassnacht M, Kroiss M, Eisenhofer G, Grossman A, Pacak K. Personalized management of pheochromocytoma and paraganglioma. Endocr Rev 2021:bnab019. [PMID: 34147030 DOI: 10.1210/endrev/bnab019] [Cited by in Crossref: 33] [Cited by in F6Publishing: 41] [Article Influence: 33.0] [Reference Citation Analysis]
9 Kumar V, Vashishta M, Kong L, Wu X, Lu JJ, Guha C, Dwarakanath BS. The Role of Notch, Hedgehog, and Wnt Signaling Pathways in the Resistance of Tumors to Anticancer Therapies. Front Cell Dev Biol 2021;9:650772. [PMID: 33968932 DOI: 10.3389/fcell.2021.650772] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 23.0] [Reference Citation Analysis]
10 Schmidtova S, Kalavska K, Liskova V, Plava J, Miklikova S, Kucerova L, Matuskova M, Rojikova L, Cierna Z, Rogozea A, Konig H, Albany C, Mego M, Chovanec M. Targeting of Deregulated Wnt/β-Catenin Signaling by PRI-724 and LGK974 Inhibitors in Germ Cell Tumor Cell Lines. Int J Mol Sci 2021;22:4263. [PMID: 33923996 DOI: 10.3390/ijms22084263] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
11 Jin XF, Spöttl G, Maurer J, Nölting S, Auernhammer CJ. Antitumoral Activity of the MEK Inhibitor Trametinib (TMT212) Alone and in Combination with the CDK4/6 Inhibitor Ribociclib (LEE011) in Neuroendocrine Tumor Cells In Vitro. Cancers (Basel) 2021;13:1485. [PMID: 33807122 DOI: 10.3390/cancers13061485] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
12 Weich A, Rogoll D, Gawlas S, Mayer L, Weich W, Pongracz J, Kudlich T, Meining A, Scheurlen M. Wnt/β-Catenin Signaling Regulates CXCR4 Expression and [68Ga] Pentixafor Internalization in Neuroendocrine Tumor Cells. Diagnostics (Basel) 2021;11:367. [PMID: 33671498 DOI: 10.3390/diagnostics11020367] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Xiong K, Niu J, Zheng R, Liu Z, Song Y, Wang L, Zhu C, Fan L. The Role of β-Catenin in Th1 Immune Response against Tuberculosis and Profiles of Expression in Patients with Pulmonary Tuberculosis. J Immunol Res 2021;2021:6625855. [PMID: 33628846 DOI: 10.1155/2021/6625855] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Brandi ML, Agarwal SK, Perrier ND, Lines KE, Valk GD, Thakker RV. Multiple Endocrine Neoplasia Type 1: Latest Insights. Endocr Rev 2021;42:133-70. [PMID: 33249439 DOI: 10.1210/endrev/bnaa031] [Cited by in Crossref: 25] [Cited by in F6Publishing: 31] [Article Influence: 12.5] [Reference Citation Analysis]